Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.09 +2.38 (+4.90%)
Delayed Quote Updated: 12:09 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment response 
From Alamar Biosciences, Inc.
Via GlobeNewswire
News headline image
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB)
From GSK plc
Via Business Wire
News headline image
Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
From GSK plc
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Core Restore Founder Ann Peets Announces Bladder Leak Treatments In Charleston
Via Press Release Distribution Service
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Via Investor Brand Network
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
From BioMedWire
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
From GSK plc
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), SUNation Energy, Inc. (Nasdaq – SUNE), Organon & Co. (NYSE – OGN), Taylor Morrison Home Corporation (NYSE – TMHC)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
From GSK plc
Via Business Wire
News headline image
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
From GSK plc
Via Business Wire
News headline image
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
From Bora Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
From GSK plc
Via Business Wire
News headline image
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026
From GSK plc
Via Business Wire
News headline image
GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million
From GSK plc
Via Business Wire
News headline image
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
From GSK plc
Via Business Wire
News headline image
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
From GSK plc
Via Business Wire
News headline image
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level
From GSK plc
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
From Pomerantz LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.